A Bayesian dose-finding design for drug combination trials with delayed toxicities
DOI10.1214/13-BA839zbMATH Open1329.62431WikidataQ39125629 ScholiaQ39125629MaRDI QIDQ908029FDOQ908029
Publication date: 2 February 2016
Published in: Bayesian Analysis (Search for Journal in Brave)
Full work available at URL: https://projecteuclid.org/euclid.ba/1378729925
Recommendations
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
- Adaptive Bayesian compound designs for dose finding studies
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Bayesian design for clinical trials with a constraint on the total available dose
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- scientific article; zbMATH DE number 1154647
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Sampling theory, sample surveys (62D05) Optimal statistical designs (62K05) Sequential statistical design (62L05) Robustness and adaptive procedures (parametric inference) (62F35)
Cited In (13)
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
- Constructing Release Targets for Drug Products: A Bayesian Decision Theory Approach
- Adaptive designs for drug combination informed by longitudinal model for the response
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
- A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome
- Application of gamma process to two-agent combinations with delayed toxicity
This page was built for publication: A Bayesian dose-finding design for drug combination trials with delayed toxicities
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q908029)
